Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review

Journal of Dermatological Treatment

Volumn 18, Issue 4, 2007, Pages 223-242

  Garduno, Javier ^a   Bhosle, Monali J ^b   Balkrishnan, Rajesh ^b   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Disease severity; Outcomes; PASI; Psoriasis; Quality of life

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; HEALTH STATUS; HUMAN; META ANALYSIS; PHYTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 34547646308     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701271807     Document Type: Review

References (38)

1. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al.; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-89.
2. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-36.
3. Chladek J, Grim J, Martinkova J, Simkova M, Vaneckova J. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol. 2005;96:247-8.
4. Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15:37-9.
5. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al.; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7.
6. Moller K, Sollerman C, Geijer M, Kopylov P, Tagil M. Avanta versus Swanson silicone implants in the MCP joint-a prospective, randomized comparison of 30 patients followed for 2 years. J Hand Surg [Br]. 2005;30:8-13.
7. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64.
8. Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-80.
9. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
10. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31:1356-61.
11. Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis. 2004;63:769-73.
12. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al.; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939-50.
13. Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, et al. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann Rheum Dis. 2004;63:718-22.
14. Kovarik JM, Schmouder RL, Barilla D, Buche M, Rouilly M, Berthier S, et al. FTY720 and cyclosporine: Evaluation for a pharmacokinetic interaction. Ann Pharmacother. 2004;38(7-8):1153-8.
15. Feliciani C, Zampetti A, Forleo P, Cerritelli L, Amerio P, Proietto G, et al. Nail psoriasis: Combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004;8:122-5.
16. Sanchez Ruderisch H, Aryee-Boi J, Schwarz C, Radenhausen M, Tebbe B. Shower PUVA: A novel variant of photochemotherapy. Distribution of photosensitivity and accumulation of trioxsalen in the skin. Skin Pharmacol Physiol. 2004;17:129-32.
17. Scott G, Osborne SA, Greig G, Hartmann S, Ebelin ME, Burtin P, et al. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. Clin Pharmacokinet. 2003;42:1305-14.
18. Takada K, Danning CL, Kuroiwa T, Schlimgen R, Tassiulas IO, Davis JC Jr, et al. Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: Clinical and immunological effects. Ann Rheum Dis. 2003;62:1112-15.
19. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol. 2003;49:816-25.
20. Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: Evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone. 2003;33:575-81.
21. Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology. 2003;207:166-72.
22. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: An open, prospective study. Br J Dermatol. 2003;149:207-9.
23. Pestelli E, Floriani I, Fabbri P, Caproni M. Cetirizine modulates adhesion molecule expression in a double-blind controlled study conducted in psoriatic patients. Int J Tissue React. 2003;25:1-8. Erratum in: Int J Tissue React. 2003;25:79.
24. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol. 2003;42:572-5.
25. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002;29(5-6):415-26.
26. Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA. 2003;289:1274-7.
27. Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology. 2003;206:153-6.
28. Gandham SG, Menon D. Prospective randomised trial comparing traditional suture technique with the dynamic sliding loop suture technique in the closure of skin lacerations. Emerg Med J. 2003;20:33-6.
29. Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: Is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol. 2002;147:122-9.
30. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: A placebo-controlled, double-blind study. J Cutan Med Surg. 2001;5:299-302.
31. Behrens-Williams SC, Kraus D, Reuther T, Kerscher MJ. Do we alter ultraviolet sensitivity in vivo with stratum corneum rehydration? A pilot study and review of the literature. Br J Dermatol. 2002;146:280-4.
32. Friedrich M, Sterry W, Klein A, Ruckert R, Docke WD, Asadullah K. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Derm Venereol. 2001;81:429-30.
33. Sakurane M, Shiotani A, Furukawa F. Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients. J Dermatol. 2002;29:23-7.
34. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: A double-blind, randomized, vehicle-controlled study. Cutis. 2001;68:355-8.
35. Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: A randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145:546-53.
36. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001;28:2274-82.
37. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol. 2001;167:4075-82.
38. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial. Lancet. 2001;357:2012-16.